Professors

Sophie Visvikis-Siest

  • Faculty: genetics and atherosclerosis
  • Degrees: Head of Laboratory of molecular diagnostics

She obtained a diploma of Biology at the University of Athens (Greece). She received a master on Biochemistry, Pharmacology before obtaining a PhD on Genetic Epidemiology of Cardiovascular Diseases at the University of Nancy.

She is Researcher at the Institute of National Health and Medical Research (INSERM) from 1989 and in 2001 became Director of Research at INSERM.

From 1999 to 2009, she had the direction of an INSERM Research team in Nancy “Gene Environment Interactions and Cardiovascular Diseases” and then of a Research Unit in the University of Lorraine.

From January 2013, she is director of the Research Unit INSERM UMR U 1122;‘Interactions Géne-Environement en Physiopathologie Cardio-Vasculaire’ (IGE-PCV) at the University of Lorraine (http://www.u1122.inserm.fr/en/).

She has the direction of a Biological Ressources Center (BRC):Interactions ‘Géne-Environement en Physiopathologie Cardio-Vasculaire’ (IGE-PCV) from 2002.

Dr Sophie Visvikis-Siest main research interests are in the domain of cardio-vascular diseases; genetic epidemiology; ‘-omics’ stratified medicine; pharmacogenomics and inflammation.

She has a 20-years’ experience in the prevention field by her involvement in the Centre of Preventive Medicine in Vandoeuvre-lès-Nancy, France.

She is the scientific director of the STANISLAS Cohort origin project based on1006 families followed for 15 years.

She has published more than 320 papers in international scientific committee journals (index h: 45) and gave more than 70 conferences under invitation.

Dr Sophie Visvikis-Siest participates in various French and International Societies of genetics and atherosclerosis. She has consultants and grants activities for public and private companies such as: ‘Center of Preventive Medicine’ (France), ‘GlaxoSmithKline’ (Italy), ‘Servier’ (France), ‘Roche molecular systems’ (Alameda, USA), ‘Randox’ (Belfast, UK), ‘Biologie Prospective’ (France).

She has a long studying Research experience in acquisition and successful execution of public, academic, industrial and EC founded projects such as: EARS, European Atherosclerosis Research Study; ApoEUROPE, BIOMED2; Interreg IIIA « Pôle de Prévention Cardiovasculaire Transfrontalier: Un Réseau d’Etudes et d’Actions Communes de Prévention Cardiovasculaire »; Ingenious HyperCare; NoE and BioIntelligence.

She participates in BBMRI (Biobanking and Biomolecular Resources Research Infrastructure) European Biobanking initiative and is one of the pioneers in Biobanking founded by INSERM and ANR in France.

Besides her Research activities, she is teaching genetic epidemiology of cardio-vascular diseases.

She is board member and vice-president of the European Society of Predictive Medicine from its creation at 2009 (www.euspm.org).

She is board member, treasurer and chair of the ‘meetings’ division of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) from 2011(www.esptnet.eu).

She is also involved in the scientific organization of several congresses, meetings and courses, in France and abroad and also responsible with G. Siest of their own meetings named “Santorini Conferences” held every 2 years since 2002 in the domain of genomics, pharmacogenomics and personalised medicine.

 

Publications

  • Stathopoulou MG, Monteiro P., Shahabi P, Penas-Lledo E., El Shamieh S., Silva Santos L, Thilly N, Siest G, Llerena A, Visvikis-Siest S. Newly identified synergy between Clopidogrel and calcium-channel blockers for blood pressure regulation possibly involves CYP2C19 rs4244285. Int J Cardiol. 2013 in press.
  • Stathopoulou MG, Bonnefond A, Ndiaye NC, Azimi-Nezhad M, El Shamieh S,Saleh A, Rancier M, Siest G, Lamont J, Fitzgerald P, Visvikis-Siest S. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J Lipid Res. 2013;54(2):535-41.
  • Froguel P*, Ndiaye NC*, Bonnefond A, Bouatia-Naji N, Dechaume A, Siest G, Herbeth B, Falchi M, Bottolo L, Guéant-Rodriguez RM, Lecoeur C, Langlois MR, Labrune Y, Ruokonen A, El Shamieh S, Stathopoulou MG, Morandi A, Maffeis C, Meyre D, Delanghe JR, Jacobson P, Sjöström L, Carlsson LM, Walley A, Elliott P, Jarvelin MR, Dedoussis GV, Visvikis-Siest S. A Genome-Wide Association Study Identifies rs2000999 as a Strong Genetic Determinant of Circulating Haptoglobin Levels. PLoS One. 2012; 7(3):e32327. *co-first authors.
  • El Shamieh S, Ndiaye NC,Stathopoulou M, Murray H, Masson C, Lamont J, FitzGerald PS, Benetos A, Visvikis-Siest S. Functional epistatic interaction between rs6046G>A in F7 and rs5355C>T in SELE modifies systolic blood pressure levels. PLoS ONE 2012; 7(7):e40777 .
  • Debette S*, Visvikis-Siest S*, Chen MH, Ndiaye NC, Song C, DeStefano AL, Safa R, Azimi-Nezhad M, Sawyer D, Marteau JB, Xanthakis V, Siest G, Sullivan L, Pfister M, Smith H, Choi SH, Lamont J, Lind L, Yang Q, Fitzgerald P, Ingelsson E, Vasan RS, Seshadri S. Identification of cis and trans acting genetic variants explaining up to half the variation in circulating VEGF levels. Circ Res. 2011; 109(5):554-63. *co-first authors.